Back to Search
Start Over
Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication
- Source :
- Drugs - Real World Outcomes, Vol 6, Iss 3, Pp 133-140 (2019)
- Publication Year :
- 2019
- Publisher :
- Adis, Springer Healthcare, 2019.
-
Abstract
- Abstract Introduction A Direct Healthcare Professional Communication (DHPC) sent in Denmark on 11 August 2011 provided information on new pioglitazone labelling and guidance on monitoring treatment effectiveness. We describe pioglitazone use in Denmark after the DHPC, estimate the incidence of heart failure (HF), quantify pioglitazone cessation following a diagnosis of bladder cancer (BC) or uninvestigated macroscopic haematuria, and describe glycated haemoglobin (HbA1c) values. Methods This was a cohort study. From Danish population-based registries, cohorts of type 2 diabetes mellitus incident or prevalent users of pioglitazone or insulin in 2011–2015 were created. Patient characteristics, treatment patterns, laboratory results (available for a regional subset of the population), and incidence rates of HF and BC were estimated. Results There were 80 pioglitazone and 17,699 insulin incident users, 140 pioglitazone and 13,183 insulin prevalent users. There were no new BC cases among incident pioglitazone users, and
- Subjects :
- Therapeutics. Pharmacology
RM1-950
Pharmacy and materia medica
RS1-441
Subjects
Details
- Language :
- English
- ISSN :
- 21991154 and 21989788
- Volume :
- 6
- Issue :
- 3
- Database :
- Directory of Open Access Journals
- Journal :
- Drugs - Real World Outcomes
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f26f531dda074aa08f54e74e4239463d
- Document Type :
- article
- Full Text :
- https://doi.org/10.1007/s40801-019-0160-6